Federal officials are predicting doom because a Pennsylvania woman became infected with a germ that can’t be stopped by most antibiotics. “The medicine cabinet is empty for some patients,” warned Centers for Disease Control and Prevention Director Thomas Frieden last week.
You’d think the CDC was finally ready to get serious about drug-resistant infections. Think again. The CDC watched “superbugs” spread across the nation, and dawdled. Centers for Denial and Confusion is more like it.
The Pennsylvania woman’s infection is resistant to a last-resort antibiotic called colistin. This is the first case, as far as we know, of an infection resistant to colistin in the U.S. , but thousands of patients die every year from infections resistant to more commonly used antibiotics.
As antibiotics lose their punch, medical care becomes riskier, especially in hospitals. Patients who need chemotherapy or surgery rely on antibiotics. Without them, even a routine procedure – bypass surgery, or C-section – could turn deadly.
The medical community has struggled with drug-resistance for half a century. There’s no avoiding it. Bacteria naturally evolve to resist weapons we use to fight them.
CRE – carbapenem-resistant infections – have plagued New York-area hospitals for fifteen years. CRE bloodstream infections have a 50% death rate. In 2011, a New York patient transferred to the National Institutes of Health in Bethesda, Md., carried the germ with her, starting an outbreak that killed several patients, including a 16-year-old boy. Yet the CDC waited until 2013 to sound the alarm about this “nightmare bacteria.” And has done little since.
Three aggressive steps are needed to protect patients, but the CDC has gotten serious about only one: curbing over-use of antibiotics. The agency is MIA on the need for rigorous cleaning and screening incoming patients for superbugs.